The pathway map for a specific asset and indication — precedent approvals, division history, advisory-committee posture, expedited-program eligibility, and the open scientific questions the agency is most likely to raise.
A specific clinical asset is approaching a regulatory inflection — pre-IND, end-of-Phase-2, BLA strategy — and the team needs an outside read on what the agency will actually focus on, not a generic landscape map.
For our second-generation oral TPO receptor agonist in chronic ITP, which precedent approval is the closer regulatory analogue — eltrombopag or avatrombopag — and what does that imply for our endpoint, dose-titration design, and FDA division alignment?
End-to-end pre-clinical-to-IND intelligence on a single program: regulatory pathway, competitive set, IP terrain, and a defensible clinical-development plan, integrated rather than stitched together.
An investor, a corporate development team, or an internal program lead needs one document that answers the regulatory, competitive, IP, and clinical-design questions in a single, defensible read — rather than four reports from four firms.
For the lead asset in this seed-stage company's deck — a small molecule against a fibrosis target — what's the realistic path to IND, who else is in the same lane, where is the IP soft, and what does a credible Phase-1 actually look like?
Dedicated, ongoing coverage of a therapeutic area, pipeline, or competitive set — structured as standing memos, ad-hoc briefings, and a working call cadence rather than a quarterly slide refresh.
A strategy team or executive group needs sustained coverage of a specific area — an immuno-oncology subfield, a payer-access category, a competitor pipeline — and the database subscription isn't doing the synthesis the team actually needs.
Cover the global ADC competitive set in HER2-low breast cancer for the next two quarters — tell us before, not after, every meaningful clinical or regulatory event, and tell us what it means for our positioning.
The Sponsor's asset — a second-generation, once-daily oral TPO receptor agonist with a non-overlapping binding footprint — will be reviewed by the Division of Non-Malignant Hematology, the same division that handled both eltrombopag (NDA 022291)[1] and avatrombopag (NDA 210238)[2]. The Sponsor's working assumption, as reviewed in our kickoff, is that either approval can serve as a regulatory analogue. That assumption does not survive the review record.
The two precedents diverge sharply on three dimensions the agency treats as load-bearing for a third-in-class entrant: durable-platelet-response endpoint definition, the role of dose titration, and hepatotoxicity surveillance. Eltrombopag's 2008 approval (FDA-2008-N-0473)[3] established the original primary-endpoint convention — platelet count ≥ 50×10⁹/L — but carried a Boxed Warning for hepatotoxicity that has shaped every subsequent label in the class. Avatrombopag's 2018 approval reframed the endpoint as durable response over six months and explicitly avoided the hepatotoxicity warning on the basis of a structurally distinct binding mode and a clean LFT signal across pivotal studies.[4]
The closer analogue, on the strength of the review correspondence, is avatrombopag. Three reasons. First, the Division's preferred endpoint frame in the 2018–2020 review cycle shifted decisively toward durable response, and the Sponsor's pivotal protocol is already structured that way. Second, the avatrombopag review package is the more recent expression of Division thinking on titration schemas, and the Sponsor's once-daily dosing avoids the meal-timing concession that constrained eltrombopag's label.[5] Third, the advisory-committee posture in 2018 (no AdCom convened) is a useful prior for a clean Phase-3 readout.
The risk vector is not the precedent itself. It is the second-generation framing. Reviewers will read the Sponsor's package against the cumulative class label, not against avatrombopag in isolation. We expect three specific scientific questions to recur in pre-IND and Type-B correspondence; they are itemised in §3.3.
Every engagement holds to the same evidentiary discipline — the same one a regulator, a court, or an investment committee would expect. The four notes below describe what that discipline is and where it ends.
New engagements begin with a 60-minute scoping call. We don't ask you to fill in a form — we ask you to describe the decision in front of you, and we send you back a one-page brief with the question framed in writing.